Paris, France, April 23, 2024 – Vivet Therapeutics (“Vivet”), a clinical stage biotech company developing novel and long-lasting gene therapies for rare inherited liver metabolic disorders, is pleased to announce that its management team will be participating and presenting at the following scientific and business conferences in April, May and June in 2024.
Vivet Therapeutics gene therapy creation platform is yielding multiple, highly promising gene therapies for rare inherited, liver metabolic disorders with long lasting therapeutic benefits. The Company is currently progressing in a Phase 1/2 GATEWAY trial for the treatment of Wilson Disease (WD) with lead program VTX-801, and has dosed its first patient in Cohort 2, following encouraging safety, tolerability and early signs of pharmacological effects in patients in Cohort 1. Its second clinical program, VTX-PID is currently advancing in a Phase 1 trial and has the potential to overcome unhelpful neutralizing antibodies (NAbs) that patients may have developed due to exposure to “wild-type” Adeno-Associated Virus (AAVs) or from prior treatment with therapies that use AAVs.
Further updates on Vivet’s gene therapy platform which has initiated two clinical and four pre-clinical assets to date will be shared at upcoming scientific conferences in 2024.
Current Situation of Rare Diseases in Spain Roundtable
Date & location: 23 April, Madrid, Spain
Roundtable title: Therapeutic Advances on the Current Situation of Rare Diseases in Spain
Participating: Gloria Gonzalez-Aseguinolaza, Co-Founder & Chief Scientific Officer
Roundtable date & time: 23 April, 13.00 CEST
LSX 10th Annual World Congress
Date & location: 29-30 April, London, UK
Session title: Biotech Leaders – Capital Markets & Investments
Panel title: Investing in a Sound Cell & Gene Therapy Clinical Strategy to Guarantee Funding Success
Participating: Jean-Philippe Combal, Co-Founder & Chief Executive Officer
Panel date & time: 30 April, 12.00 – 12.50 BST
American Society of Gene & Cell Therapy (ASGCT)
Date & location: 7-11 May, Baltimore, MD, US
Presentation title: S/MAR-Containing AAV Vectors Result in an Increase in AVV Episomes & a Reduction in AAV Integration Sites in a Mouse Model with a High Rate of Hepatocyte Proliferation
Presenting: Jean-Philippe Combal, Co-Founder & Chief Executive Officer, Dr Gloria Gonzalez-Aseguinolaza, Co-Founder & Chief Scientific Officer, Veronica Ferrer, Senior Project Leader & Andrea Llanos-Ardaiz, PhD
Presentation date & time: 10 May at 13.00 – 13.45 EDT
24th Bio€quity Europe
Date & location: 12-14 May, San Sebastian, Spain
Presentation title: Company Presentation
Presenting: Jean-Philippe Combal, Co-Founder & Chief Executive Officer & Susan Coles, General Counsel & Head of Finance
Presentation date & time: 13 May, 17.15 CEST
5th Annual Gene Therapy Analytical Development Europe Summit
Date & location: 22-24 May, London, UK
Session title: Regulatory Guidance on Analytical Development
Panel title: Unpicking the Complexities of Batch-Batch Variability to Enable the Setting of Feasible Thresholds & Avoid Regulatory Obstacles
Participating: Anne Douar, Chief Operating Officer
Panel date & time: 23 April, 15.15 BST
4th Annual Gene Therapy Patient Engagement
Date & location: 29-31 May, Boston, MA, US
Attending: Sonia Valero, Head of Clinical Operations and Patient Advocacy
European Association for the Study of the Liver (EASL) Congress
Date & location: 5-8 June, Milan, Italy
Presentation title: Interim safety results of the ongoing international Phase I/II GATEWAY gene therapy trial with VTX-801 conducted in adult patients with Wilson disease
Presenting: Dr Thomas Damgaard Sandahl, Wilson Disease expert, Arhaus University
Presentation date & time: 5 June, 08.30 – 18.00 CEST
CTX Alliance Annual Patient Meeting
Date & location: 28 June, Itasca, IL, USA
Presentation title: Potential gene therapy for CTX and insights from CYP27A1 KO mouse model
Presenting: Dr Gloria Gonzalez-Aseguinolaza, Co-Founder & Chief Scientific Officer
Presentation date & time: 28th June at 1:25-1:50pm CST
If you would like to meet with the Vivet Therapeutics team at any of the above events, please contact us at info@vivet-theraputics.com. For more information, please visit us at vivet-therapeutics.com.
About Vivet Therapeutics
Vivet Therapeutics is a private, clinical-stage biotech company developing novel and long-lasting gene therapies for rare inherited metabolic conditions, including Wilson’s Disease. Vivet’s gene therapy platform uses recombinant adeno-associated viruses (rAAVs) as vectors and has initiated two clinical programs and four pre-clinical assets to date. Its most advanced therapy is VTX-801, a novel gene therapy for Wilson’s Disease, with key clinical read-outs expected by the end of 2024. Vivet Therapeutics was founded in 2016 by CEO Dr Jean-Philippe Combal and CSO Dr Gloria Gonzalez-Aseguinolaza and is led by a highly experienced management team with deep expertise developing gene therapies and orphan drugs.
Vivet Therapeutics is backed by international life science investors including Novartis Venture Fund, Roche Venture Fund, HealthCap, Pfizer Inc., Columbus Venture Partners, Ysios Capital, Kurma Partners and Eurazeo. In 2019, key investor Pfizer contributed a €45M investment to collaborate with Vivet in recognition of its scientific expertise and innovative technology platforms.
For more information, please visit www.vivet-therapeutics.com – Follow us on LinkedIn @Vivet Therapeutics and Twitter @Vivettherapeutics
For further information, please contact:
Optimum Strategic Communications
Mary Clark, Zoe Bolt, Vareen Outhonesack
Tel: +44 (0) 20 3882 9621
Email: vivet@optimumcomms.com